Shionogi & Co., Ltd. engages in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. Shionogi & Co., Ltd. is based in Osaka, Japan.
| Revenue (Most Recent Fiscal Year) | $2.88B |
| Net Income (Most Recent Fiscal Year) | $1.12B |
| PE Ratio (Current Year Earnings Estimate) | 11.68 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 1.92 |
| Price to Sales Ratio (Trailing 12 Months) | 4.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.58 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.30 |
| Pre-Tax Margin (Trailing 12 Months) | 45.81% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 6.63 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.13 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | 0.97 |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.29 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $0.66 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 1.70B |
| Free Float | -- |
| Market Capitalization | $14.21B |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 0.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 1.92% |
| Annual Dividend (Based on Last Quarter) | $0.15 |
| Dividend Yield (Based on Last Quarter) | 1.83% |